{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:03:32Z","timestamp":1792602212696,"version":"4.5.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective comparative effectiveness research study assessed deidentified claims from the OptumLabs Data Warehouse from individuals aged 16 years or older with OUD and commercial or Medicare Advantage coverage. Opioid use disorder was identified based on 1 or more inpatient or 2 or more outpatient claims for OUD diagnosis codes within 3 months of each other; 1 or more claims for OUD plus diagnosis codes for opioid-related overdose, injection-related infection, or inpatient detoxification or residential services; or MOUD claims between January 1, 2015, and September 30, 2017. Data analysis was performed from April 1, 2018, to June 30, 2019.<\/jats:p><\/jats:sec>Exposures<\/jats:title>One of 6 mutually exclusive treatment pathways, including (1) no treatment, (2) inpatient detoxification or residential services, (3) intensive behavioral health, (4) buprenorphine or methadone, (5) naltrexone, and (6) nonintensive behavioral health.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Opioid-related overdose or serious acute care use during 3 and 12 months after initial treatment.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 40\u202f885 individuals with OUD (mean [SD] age, 47.73 [17.25] years; 22\u202f172 [54.2%] male; 30\u202f332 [74.2%] white) were identified. For OUD treatment, 24\u202f258 (59.3%) received nonintensive behavioral health, 6455 (15.8%) received inpatient detoxification or residential services, 5123 (12.5%) received MOUD treatment with buprenorphine or methadone, 1970 (4.8%) received intensive behavioral health, and 963 (2.4%) received MOUD treatment with naltrexone. During 3-month follow-up, 707 participants (1.7%) experienced an overdose, and 773 (1.9%) had serious opioid-related acute care use. Only treatment with buprenorphine or methadone was associated with a reduced risk of overdose during 3-month (adjusted hazard ratio [AHR], 0.24; 95% CI, 0.14-0.41) and 12-month (AHR, 0.41; 95% CI, 0.31-0.55) follow-up. Treatment with buprenorphine or methadone was also associated with reduction in serious opioid-related acute care use during 3-month (AHR, 0.68; 95% CI, 0.47-0.99) and 12-month (AHR, 0.74; 95% CI, 0.58-0.95) follow-up.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Treatment with buprenorphine or methadone was associated with reductions in overdose and serious opioid-related acute care use compared with other treatments. Strategies to address the underuse of MOUD are needed.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2019.20622","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T16:31:17Z","timestamp":1580920277000},"page":"e1920622","source":"Crossref","is-referenced-by-count":958,"title":["Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder"],"prefix":"10.1001","volume":"3","author":[{"given":"Sarah E.","family":"Wakeman","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Larochelle","sequence":"additional","affiliation":[{"name":"Clinical Addiction Research and Education Unit, Boston Medical Center, Boston, Massachusetts"},{"name":"Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Ameli","sequence":"additional","affiliation":[{"name":"Integrated Programs, OptumLabs Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Chaisson","sequence":"additional","affiliation":[{"name":"Integrated Programs, OptumLabs Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Thomas","family":"McPheeters","sequence":"additional","affiliation":[{"name":"Department of Research, OptumLabs, Minnetonka, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Crown","sequence":"additional","affiliation":[{"name":"Department of Research, OptumLabs, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Azocar","sequence":"additional","affiliation":[{"name":"Department of Research, Optum Behavioral Health, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshak M.","family":"Sanghavi","sequence":"additional","affiliation":[{"name":"Department of Medicare and Retirement, United Healthcare, Minnetonka, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"issue":"5152","key":"zoi190774r1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and opioid-involved overdose deaths\u2013United States, 2013-2017.","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi190774r2","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1097\/QAI.0000000000001426","article-title":"Brief report: nonfatal overdose events among persons who inject drugs: findings from seven national HIV behavioral surveillance cities 2009 & 2012.","volume":"75","author":"Robinson","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"zoi190774r3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.15585\/mmwr.mm6701a5","article-title":"HIV infection and HIV-associated behaviors among persons who inject drugs\u201420 cities, United States, 2015.","volume":"67","author":"Burnett","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"zoi190774r4","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/add.v112.9","article-title":"Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001-12.","volume":"112","author":"Hsu","year":"2017","journal-title":"Addiction"},{"issue":"2","key":"zoi190774r5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014.","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am J Public Health"},{"issue":"10","key":"zoi190774r6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.15585\/mmwr.mm6810a6","article-title":"Notes from the field: HIV diagnoses among persons who inject drugs\u2013Northeastern Massachusetts, 2015-2018.","volume":"68","author":"Cranston","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"zoi190774r7","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.1503\/cmaj.180694","article-title":"The risk of infective endocarditis among people who inject drugs: a retrospective, population-based time series analysis.","volume":"191","author":"Weir","year":"2019","journal-title":"CMAJ"},{"issue":"2","key":"zoi190774r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7621","article-title":"Prevention of prescription opioid misuse and projected overdose deaths in the United States.","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"zoi190774r9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis.","volume":"71","author":"Ciccarone","year":"2019","journal-title":"Int J Drug Policy"},{"key":"zoi190774r11","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"zoi190774r12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jsat.2015.05.001","article-title":"Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history.","volume":"57","author":"Clark","year":"2015","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"zoi190774r13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/add.v111.4","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial.","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"key":"zoi190774r14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"zoi190774r15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi190774r16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/hesr.2019.54.issue-2","article-title":"County-level access to opioid use disorder medications in Medicare Part D (2010-2015).","volume":"54","author":"Abraham","year":"2019","journal-title":"Health Serv Res"},{"issue":"1","key":"zoi190774r17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jrh.2019.35.issue-1","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update.","volume":"35","author":"Andrilla","year":"2019","journal-title":"J Rural Health"},{"issue":"1","key":"zoi190774r18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities.","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"zoi190774r19","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment.","volume":"105","author":"Jones","year":"2015","journal-title":"Am J Public Health"},{"issue":"8","key":"zoi190774r20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014.","volume":"171","author":"Hadland","year":"2017","journal-title":"JAMA Pediatr"},{"key":"zoi190774r21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.","volume":"85","author":"Morgan","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"zoi190774r22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5055\/jom.2017.0389","article-title":"Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse.","volume":"13","author":"Wollschlaeger","year":"2017","journal-title":"J Opioid Manag"},{"key":"zoi190774r23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"zoi190774r25","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1524-4733.2009.00600.x","article-title":"Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report, part I.","volume":"12","author":"Berger","year":"2009","journal-title":"Value Health"},{"issue":"11","key":"zoi190774r26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"10","key":"zoi190774r27","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1001\/jama.283.10.1303","article-title":"Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial.","volume":"283","author":"Sees","year":"2000","journal-title":"JAMA"},{"issue":"12","key":"zoi190774r28","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"zoi190774r29","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care\u2013based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi190774r30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.drugpo.2013.03.005","article-title":"Defining a service for people who use drugs as \u2018low-threshold\u2019: what should be the criteria?","volume":"24","author":"Mofizul Islam","year":"2013","journal-title":"Int J Drug Policy"},{"issue":"3","key":"zoi190774r31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2012.08.002","article-title":"Thresholds in a low-threshold setting: an empirical study of barriers in a centre for people with drug problems and mental health disorders.","volume":"24","author":"Edland-Gryt","year":"2013","journal-title":"Int J Drug Policy"},{"issue":"3","key":"zoi190774r32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/add.13622","article-title":"Patient-centered methadone treatment: a randomized clinical trial.","volume":"112","author":"Schwartz","year":"2017","journal-title":"Addiction"},{"issue":"3","key":"zoi190774r33","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2105\/AJPH.2018.304856","article-title":"Impact of Medicaid restrictions on availability of buprenorphine in addiction treatment programs.","volume":"109","author":"Andrews","year":"2019","journal-title":"Am J Public Health"},{"issue":"6","key":"zoi190774r34","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1111\/1475-6773.12201","article-title":"The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.","volume":"49","author":"Clark","year":"2014","journal-title":"Health Serv Res"},{"issue":"10118","key":"zoi190774r35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"zoi190774r36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/biostatistics\/kxh019","article-title":"Sensitivity analysis for informative censoring in parametric survival models.","volume":"6","author":"Siannis","year":"2005","journal-title":"Biostatistics"},{"key":"zoi190774r24","author":"OptumLabs","year":"2019"},{"key":"zoi190774r10","unstructured":"The National Academies of Science, Engineering, and Medicine. Medications for opioid use disorder save lives. March 20, 2019. http:\/\/www.nationalacademies.org\/hmd\/Reports\/2019\/medications-for-opioid-use-disorder-save-lives.aspx. Accessed March 26, 2019."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2760032\/wakeman_2020_oi_190774_1716479457.97471.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T15:00:47Z","timestamp":1717167647000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2760032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]}}}